View original post here:
Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights
Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
Read the original post:
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update
MDxHealth Reports Preliminary 2022 Revenues and Reaffirms 2023 Revenue Guidance
New Approaches to Treating Infections in Cystic Fibrosis Patients – AR 501 Phase 2 Trial Update
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia,…
Psyence Announces Business Combination between Wholly Owned Subsidiary Psyence Biomed Corp. and Nasdaq listed Newcourt Acquisition Corp
DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial
CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023
CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO
BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165
See the article here:
BioNTech Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165
Physicians for Informed Consent Sues State of California, Argues That Doctor Censorship Bill AB 2098 Violates the U.S. Constitution
NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at…
ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common Stock
Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and CHK-336 Preclinical Efficacy…
hC Bioscience Announces Extension of Series A to $40 Million
Read the original post:
hC Bioscience Announces Extension of Series A to $40 Million